IOVA Iovance Biotherapeutics, Inc.

NASDAQ
$8.70

Iovance Biotherapeutics, Inc. (IOVA) is confirmed to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share.

Iovance Biotherapeutics Beat Consensus Estimates, Reaffirms Revenue Guidance
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.09)
Rev est $117.67M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.20

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.